| __timestamp | BioCryst Pharmaceuticals, Inc. | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 14097000000 |
| Thursday, January 1, 2015 | 13047000 | 14809000000 |
| Friday, January 1, 2016 | 11253000 | 14837000000 |
| Sunday, January 1, 2017 | 13933000 | 14784000000 |
| Monday, January 1, 2018 | 29514000 | 14455000000 |
| Tuesday, January 1, 2019 | 37121000 | 14350000000 |
| Wednesday, January 1, 2020 | 67929000 | 11615000000 |
| Friday, January 1, 2021 | 118818000 | 12703000000 |
| Saturday, January 1, 2022 | 159371000 | 13677000000 |
| Sunday, January 1, 2023 | 213894000 | 14771000000 |
| Monday, January 1, 2024 | 14730000000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Pfizer Inc. and BioCryst Pharmaceuticals, Inc. have shown contrasting approaches to handling these costs. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually. In contrast, BioCryst's expenses have surged by over 2700%, from approximately $7 million in 2014 to $214 million in 2023.
This stark difference highlights Pfizer's ability to maintain cost efficiency despite its larger scale, while BioCryst's rising expenses may reflect its aggressive growth strategy. As the pharmaceutical landscape evolves, these companies' approaches to SG&A management will be pivotal in determining their financial health and competitive edge.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Pfizer Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.